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Effluent and serum protein  
N-glycosylation is associated 
with inflammation and peritoneal 
membrane transport characteristics 
in peritoneal dialysis patients
Evelina Ferrantelli1,5, Karima Farhat2, Agnes L. Hipgrave Ederveen3, Karli R. Reiding3,  
Robert H. J. Beelen1, Frans J. van Ittersum2, Manfred Wuhrer  1,3,4 & Viktoria Dotz  3,4
Mass spectrometric glycomics was used as an innovative approach to identify biomarkers in serum 
and dialysate samples from peritoneal dialysis (PD) patients. PD is a life-saving treatment worldwide 
applied in more than 100,000 patients suffering from chronic kidney disease. PD treatment uses 
the peritoneum as a natural membrane to exchange waste products from blood to a glucose-based 
solution. Daily exposure of the peritoneal membrane to these solutions may cause complications such 
as peritonitis, fibrosis and inflammation which, in the long term, lead to the failure of the treatment. 
It has been shown in the last years that protein N-glycosylation is related to inflammatory and fibrotic 
processes. Here, by using a recently developed MALDI-TOF-MS method with linkage-specific sialic 
acid derivatisation, we showed that alpha2,6-sialylation, especially in triantennary N-glycans from 
peritoneal effluents, is associated with critical clinical outcomes in a prospective cohort of 94 PD 
patients. Moreover, we found an association between the levels of presumably immunoglobulin-G-
related glycans as well as galactosylation of diantennary glycans with PD-related complications such 
as peritonitis and loss of peritoneal mesothelial cell mass. The observed glycomic changes point to 
changes in protein abundance and protein-specific glycosylation, representing candidate functional 
biomarkers of PD and associated complications.
Peritoneal dialysis (PD) is a safe treatment modality for patients with end-stage kidney disease. PD uses a patient’s 
peritoneum as a natural membrane to remove waste products and fluid from the blood to the dialysis solution by 
using mainly glucose as osmotic agent. Currently, PD is used by >100,000 end-stage renal disease patients world-
wide and accounts for approximately 11% of the dialysis population1. However, long term exposure to PD solu-
tions is associated with functional and structural alterations of the peritoneum which include neovascularisation, 
thickening of the peritoneal membrane, peritonitis2–4 as well as epithelial-to-mesenchymal transition (EMT). The 
latter is known as a process whereby the mesothelial cells lining the peritoneal cavity lose their epithelial char-
acteristics to acquire a fibroblast-like phenotype5,6. Taken together all these events lead to ultrafiltration failure 
resulting in critical clinical outcomes7.
Besides acting as a biological barrier, the peritoneum, and more specifically its mesothelial cell monolayer, 
also functions as a secretory organ which synthesizes and secretes cytokines responsible for the regulation of 
peritoneal permeability and local host defence. During EMT, the secretion of pro-inflammatory factors8, such 
as transforming growth factor-β1 (TGFβ-1) increases significantly. Besides inducing EMT9, TGFβ-1 has been 
shown to promote peritoneal fibrosis via various pro-fibrotic events including proliferation of fibroblasts and 
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extracellular matrix deposition10. TGFβ-1-induced EMT was shown to affect cellular protein glycosylation in nor-
mal mouse mammary gland epithelial cells11 as well as cancer cells12. Loss of mesothelial cells is also represented 
by a decrease in the levels of cancer antigen 125 (CA-125), a marker of peritoneal cell mass and function13, while 
hyaluronic acid (HA) deposition is characteristic of peritoneal fibrosis subsequent to dialysis treatment14. Fibrosis 
and angiogenesis seem to occur together in the peritoneal tissues15. Consequently, an increase in TGFβ-1 levels 
is often associated with high levels of vascular endothelial growth factor (VEGF), which is known to stimulate 
angiogenesis via capillary tube formation16.
Activated mesothelial cells also produce chemotactic cytokines leading to the recruitment of leukocytes and 
rapid accumulation of neutrophils, later replaced by monocytes and/or macrophages and lymphocytes, into the 
peritoneum. This scenario is typical of a peritonitis episode, a common PD-related event driven by cytokines such 
as interleukin (IL)-6, IL-8, monocytes chemotactic protein 1 (MCP-1) and many others17.
In clinical practice, effluent markers such as IL-6 and CA-125 are used to assess peritoneal functionality and 
morphology18–20, but their role as predictors for peritoneal membrane failure is still questioned. Changes in the 
levels of cytokines detected in peritoneal effluents collected from patients indeed reflect the peritoneal morpho-
logical changes, yet only at a very late stage21. Thus, relevant predictors for PD technique failure at an earlier stage 
are still needed.
Protein losses have been considered a major drawback in PD, and have recently been investigated in a few 
PD proteomics studies. Losses of protein in PD effluent (PDE) range from 5 to 15 g/day, depending on vari-
ous factors, such as a patient’s clinical status or PD fluid composition22. When compared to the overall human 
proteome, some quantitative differences in PDE have been shown, especially regarding immune-related and 
vitamin-binding proteins, coagulation factors and apolipoproteins that are known to be locally produced by the 
peritoneum23,24. Differences in the PD proteome have been shown in patients in relation to, e.g., diabetes25, or 
different peritoneal transport characteristics25,26. However, proteomic studies are scarce and have mainly been 
conducted in small cohorts.
Moreover, little is known about PD-related protein glycosylation, which is a post-translational modification 
of influence to protein functions such as cell adhesion, signal transduction, receptor activation, molecular traf-
ficking and systemic clearance27. Protein N-glycosylation is known to be related to inflammatory28 and fibrotic29 
processes. Previously, we reported on early N-glycosylation changes in mice with zymosan-induced peritonitis by 
using linkage-specific derivatisation of sialic acids30.
In the present study we adapted this glycomic methodology to clinical PDE samples that are challenging for 
glycan analysis due to lower protein concentrations as compared to serum and due to the presence of interfering 
compounds, i.e. hexose polymers. Thus, we present a novel and attractive approach for biomarker identification 
and demonstrate that changes in the glycosylation profile are associated with PD-related complications such as 
peritonitis, inflammation and mesothelial cell loss in a prospective cohort of 94 PD patients.
Results and Discussion
Study design and glycomic profiling. Serum and effluent samples were collected from PD patients in 
6-months intervals for up to 24 months (Table 1). Clinical parameters, such as cytokine levels, peritoneal func-
tionality or adverse events were furthermore assessed (Table 2)31. To increase statistical power, data was not 
analysed per treatment group (Dianeal or Physioneal), but treatment group was included as a covariate in the 
regression models.
The N-glycomic profiles of the patients’ serum and PDE samples were acquired by MALDI-TOF-MS analysis 
after protein immobilisation, enzymatic N-glycan release, and sialic acid stabilisation with differentiation of α2,3- 
and α2,6-linked sialic acids32. Importantly, the immobilisation of proteins on PVDF membrane was necessary for 
freeing PDE samples from hexose polymers that originate from PD fluid and that would otherwise interfere with 
N-glycomic analysis (Supporting Information Fig. S-1). To ensure unambiguous mass assignment, we excluded 
15 detected compositions from further analysis due to overlapping masses of N-glycans with possible residual 
dextran interferences in the effluent. Structural features were then assigned to the remaining 26 N-glycan compo-
sitions in serum and effluent each (Fig. 1, Supporting Information Table S-1), in accordance with the established 
knowledge of the human plasma N-glycome and its biosynthetic pathways32–34. Twelve derived traits were calcu-
lated representing major structural glycomic features, i.e. complexity (high-mannosidic, di- and tri-antennary 
species), bisection, galactosylation, fucosylation, α2,3- and α2,6-sialylation, as well as the sum of presumably 
IgG-related glycans (Supporting Information Table S-2). No tetraantennary glycans were detected, which was 
attributed to the rather limited sensitivity of the workflow, most probably caused by the limited capacity of the 
Study month
Number of patients Age in years (mean ± SD)
M F M F
0 63 31 62.05 ± 12.47 59.77 ± 16.04
1–6 49 28 62.70 ± 12.66 60.35 ± 16.28
7–12 43 23 63.33 ± 12.98 58.77 ± 16.70
13–18 27 14 63.79 ± 13.15 58.82 ± 14.25
19–24 20 11 64.00 ± 13.96 58.29 ± 15.46
Table 1. Patient numbers and age at baseline and follow-up. Given are the numbers of patients (M, male/F, 
female) left at the respective time periods of sample collection for glycomic profiling and/or determination of 
clinical parameters as described in the experimental section.
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PVDF membrane used for protein immobilisation. As a comparison, when using our in-solution glycan release, 
we are able to detect more than 90 different species in human plasma and murine peritoneal effluent30,32. However, 
in the current study we chose to apply the same membrane-based sample method and data processing criteria to 
both effluent and serum, to ensure the comparability of the glycomes from the two biofluids and assess the use-
fulness of effluent samples for biomarker discovery.
Clinical parameter
Number of patients Median ± interquartile range




Time on PD (months) 62 31 16.80 ± 20.50 12.20 ± 21.50
DPCrea4 63 31 0.74 ± 0.14 0.70 ± 0.15
Ultrafiltration_PET (mL) 63 31 400.00 ± 344.30 540.00 ± 398.20
IL-6 (ρg/mL) 61 30 96.74 ± 138.87 71.16 ± 119.13
IL-8 (ρg/mL) 60 30 35.44 ± 93.00 19.81 ± 49.25
MCP-1 (ρg/mL) 61 30 247.01 ± 178.99 171.91 ± 118.38
TGFβ-1 (ρg/mL) 61 30 75.05 ± 82.78 93.43 ± 77.05
VEGF (ρg/mL) 60 29 146.94 ± 114.11 102.58 ± 140.27
CA-125 (ρg/mL) 61 30 19.60 ± 18.40 21.45 ± 13.6
HA (ρg/mL) 61 30 179.11 ± 138.27 148.52 ± 129.13
Table 2. Clinical characteristics at baseline. Given are the numbers of patients (M, male/F, female) with 
available data on the stated parameter. See Table 1 for total patient number at study month 0. The following 
clinical parameters were used as confounders for regression analysis with GEE, next to age and sex: Diabetes; 
CAPD, Continuous Ambulatory Peritoneal Dialysis; APD, Automated Peritoneal Dialysis; Dianeal or 
Physioneal treatment group; time on PD (refers to the total time in months after a patient was first introduced to 
PD treatment). The Dianeal group was randomised into two treatment groups at baseline, i.e. 27/11 male/female 
patients continued with Dianeal for 24 months, while 28/12 male/female patients switched to Physioneal for the 
following 24 months. DPCrea4 is the ratio of creatinine in the effluent vs. plasma during 4-h dwell time.
Figure 1. MALDI-TOF mass spectra of a patient’s serum (upper) and peritoneal effluent (lower) protein-
derived N-glycans. After enzymatic release of glycans, sialic acids were stabilised in linkage-specific manner 
and analysed by positive-ion reflectron mode MALDI-TOF-MS. Blue square, N-acetylglucosamine; yellow 
circle, galactose; green circle, mannose; red triangle, fucose; purple diamond oriented to the right, α2,6-linked 
N-acetylneuraminic acid; purple diamond oriented to the left, α2,3-linked N-acetylneuraminic acid; asterisks 
indicate peaks of non-N-glycan origin. Structures are proposed for the 12 most abundant species in the upper 
mass spectrum, while the lower panel contains 11 additional structures in the two zoomed areas, i.e. peaks 
1, 4, 6–8, 10, 12, 15–17, and 21. For the complete list of, in total, 26 detected glycan species, see Supporting 
Information Table S-1.
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Effluent versus serum protein glycosylation. This is the first study showing associations of the total 
protein N-glycomes in serum and effluent with important clinical parameters in PD. Associations between 
plasma N-glycans and various metabolic and inflammatory parameters were recently described in a large cohort 
of healthy individuals35. Likewise, we found associations between N-glycan features in serum as well as effluent 
from PD patients with inflammatory markers, such as IL-6 and high-sensitivity C-reactive protein (hsCRP), and, 
moreover, with PD-related parameters such as D/P creatinine after 4 hours (PET) and TGFβ-1 (Fig. 2, Supporting 
Information Fig. S-2A).
Spearman correlation analysis of the 26 glycan species detected in 91 serum and 87 PDE samples at baseline 
revealed several discrepancies between the two N-glycomic profiles, recognisable in a correlation coefficient of the 
same detected species of lower than +1 (Supporting Information Fig. S-1B). This becomes specifically apparent 
for the glycans H4N4E1F1, H5N4L1F1, H6N5L1E1, and H6N5E2F1 (peaks 8, 10, 19, and 21). In contrast, fuco-
sylated, non-sialylated diantennary glycans – both with and without bisecting GlcNAc – correlated well between 
serum and effluent (peaks 2–6 in Fig. 1 and Supporting Information Table S-1). As for serum, one may assume 
that these glycans may be largely IgG-derived36. Although we used the same laboratory procedures to prepare 
and analyse serum and PDE, technical variation may contribute to some of the observed glycomic discrepancies 
between the two sample types. Nevertheless, we expect differences to largely arise from biological sources.
When assigning the 26 detected species to 12 derived traits, correlations between serum and PDE glycans 
increased (Supporting Information Fig. S-2C). This is in line with previous reports indicating a higher technical 
robustness and often also biological relevance of derived traits in glycomic comparisons as compared to direct 
traits37,38.
At baseline, differences between serum and PDE glycosylation levels for the derived traits M, A2, A3, A2F, 
A2G, A2E, A3E, and IgG were observed in paired Wilcoxon signed-rank tests, whereas no differences could 
be found in A3F, bisection, and α2,3-sialylation (Fig. 3A, Supporting Information Fig. S-3A-C). Similar dif-
ferences were observed during the 24 months follow-up as is discussed in more detail in the following section. 
Interestingly, in a recently published study involving healthy mice, high-mannose glycans were reported to 
be more abundant in PDE than in plasma30, whereas our data in PD patients shows the reverse (Supporting 
Information Fig. S-3A). Moreover, the relative α2,6-sialylation of both di- and triantennary glycans (A2E and 
A3E) was higher in serum than in PDE (Fig. 3A), while in healthy mice we did not observe differences in overall 
or linkage-specific sialylation between plasma and peritoneal effluent N-glycans30.
N-glycan features are associated with inflammatory markers and PD-related parameters in a 
longitudinal setting. In literature, the total protein concentration in PDE is reported to remain stable over 
several months up to years on PD treatment22,39. Data on PDE protein composition over time are scarce and pro-
teomic changes, if any, are reported in studies with low statistical power40. However, pathological and morpho-
logical changes of the peritoneum can occur with duration of PD treatment and may be reflected by the effluent 
composition18. Accordingly, a few trends could be observed in our glycomics data, in particular, in the effluent 
towards the end of the study. For instance, the galactosylation of diantennary glycans (A2G) showed a downward 
Figure 2. Heatmap resulting from the t- or Wald statistics (β/SE) of the associations between clinical 
parameters and glycans from PD effluent at baseline. The ranking of the categorical variables is matching the 
listing order of their categories, e.g. for Sex, female = 0, male = 1; for the binary variables, i.e. Diabetes, Statins, 
Smoking, Betablocker, and Erythropoietin the coding was no = 0 and yes = 1. Dots refer to p < 0.05, while 
crosses represent p-values below the significance threshold corrected for multiple testing by the Bonferroni 
method (α = 0.00017). Colour codes indicate t- or Wald statistics as depicted in the colour scale to the right of 
the heat map. Hierarchical clustering (Euclidian distance, complete linkage) was applied for the sorting of the 
heatmap variables.
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trend at 24-months follow-up in the PDE, but not in serum (Fig. 3A, Supporting Information Fig. S-3D). This 
could be mainly attributed to an increase of the agalactosylated glycan compositions H3N4F1 and H3N5F1 
(Fig. 3B-D), since the relative abundance of the mono- and digalactosylated – presumably IgG-related – species 
remained stable over time in PDE (Supporting Information Fig. S-3D). A lower galactosylation of IgG is related 
to a pro-inflammatory state in different pathological conditions41,42.
Assessing the dynamic changes in glycosylation in the three treatment groups separately did not retrieve 
significant results, most likely due to a lack of statistical power (N = 9, 12, and 3 effluent glycome data pairs for 
baseline vs. 24 months in group 1, 2, and 3, respectively). However, group 2 (switched from Dianeal to Physioneal) 
did show several interesting trends (Supporting Information Fig. S-3E). For example, effluent IgG glycans tended 
to increase, while the triantennary glycan H6N5L1E2 (peak 23) decreased over time in the effluent (Supporting 
Information Fig. S-3E). The increase over time in effluent IgG glycans corresponds with the trend (Fig. 3A) in the 
total cohort and might reflect a higher level of inflammation.
The complete longitudinal dataset was assessed by logistic or linear regression in GEE analysis to reveal asso-
ciations of the serum and effluent glycans with ten selected PD-related parameters with higher statistical power 
(N = 287 and 265 glycan mass spectra for serum and effluent, respectively). To this end, 12 derived glycan traits 
were tested against peritonitis occurrence, ultrafiltration during PET, D/P creatinine after 4 hours (PET), the 
concentrations of TGFβ-1, IL-6, IL-8, MCP-1, VEGF, CA-125 and HA. In addition, two presumably IgG-related 
single N-glycan compositions were tested for their association with peritonitis based on the trends found for the 
comparison of baseline vs. 24-months follow-up (Fig. 3C and D).
Variables known to have an impact on glycosylation, in particular age and sex35 as well as diabetes, were 
included in our statistical models, since they showed a tendency to correlate with glycan features in our baseline 
assessment of the data (Fig. 2, Supporting Information Fig. S-2A). We observed an area increase in H3N5F1 (peak 
4) and a decrease in H5N4F1 (peak 5) with age in both serum and effluent, especially in women (Supporting 
Information Figure S-4). It is known that plasma protein galactosylation decreases with age in both healthy 
individuals and patients with different pathological conditions, which is mainly related to the galactosylation of 
IgG-derived glycans, including the two former-mentioned41,43. Possible confounders for PD-related parameters 
were also taken into account: treatment modality (CAPD or APD), time on PD and treatment group.
After adjustment for confounders, peritonitis occurrence, D/P creatinine after 4 hours (PET), TGFβ-1, 
IL-6, IL-8, MCP-1, VEGF, CA-125 and HA were associated with various glycan traits (Supporting Information 
Figure 3. Selected N-glycan traits from serum (Se) and effluent (Ef) over time. (A and B) Mean ± SE values 
of all patients over time classes as defined in Table 1. (A) At baseline (study month 0) all p-values were below 
the Bonferroni-adjusted significance threshold α = 0.0042 in paired Wilcoxon signed-rank tests for serum vs. 
effluent for A2G, A2E, A3E, A2F, IgG-related traits (N = 85 each); A3F was not significantly different at baseline. 
(C and D) Min/Max-values and boxplots with p-values from a paired Wilcoxon signed-rank test (two-tailed) 
for IgG-related direct traits in effluent samples from 24 patients at baseline vs. 24 months.
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Table S-3A and S-3B), as presented in the following paragraphs and summarised in Table 3. The association 
of ultrafiltration during PET with derived glycan traits was not significant after adjusting for confounders 
(Supporting Information Table S-3B).
Peritonitis occurrence. Peritonitis occurrence was positively associated with the relative abundance of 
IgG-derived glycans as well as the relative fucosylation of diantennary glycans (A2F) and α2,6-sialylation of 
triantennary glycans (A3E) in PDE only (excerpt in Table 3 and extensive information in Supporting Information 
Table S-3A). A negative association was found for the relative galactosylation (A2G) and α2,6-sialylation (A2E) 
of diantennary glycans. These associations are in line with the trends we observed towards study end, i.e. increas-
ing A2F, IgG-glycans, A3E, and decreasing A2G and A2E (Fig. 3A). This strengthens the hypothesis that these 
N-glycan traits may reflect local peritoneal inflammation in PD patients, in particular, when assessed in PDE, 
since derived glycan traits in serum were not associated with peritonitis (not shown). When analysing a subse-
lection of direct traits based on our findings for baseline and longitudinal glycan data, we found no association of 
selected triantennary α2,6-sialylated traits (peaks 16, 21, 23–24, 26) with peritonitis (data not shown). However, 
the two agalactosylated IgG-related structures (peaks 2 and 4), known for reflecting a pro-inflammatory state 
in other disease conditions41,42, were positively associated with peritonitis. These N-glycans are also the main 
contributors to the inverse association of galactosylation of diantennary glycans (A2G) with peritonitis (Table 3; 
Supporting Information Table S-3A).
PD effluent contains immunoglobulins, such as IgG and IgM44, which might reflect local inflammation dur-
ing peritonitis45, as indicated by the positive association of peritonitis with effluent but not serum glycans. In 
addition, protein losses are known to increase during peritonitis, mainly due to enhanced peritoneal membrane 
permeability caused by inflammation22,44. In a proteomic study of PDE collected from twelve patients before 
and after peritonitis, several proteins were differentially expressed. For example, fibrinogen, ceruloplasmin, 
zinc-α-2-glycoprotein and α-1-antitrypsin were downregulated during peritonitis, whereas haptoglobin and 
antithrombin-III were upregulated46. Haptoglobin and alpha1-acid-glycoprotein are acute-phase proteins that 
contribute to the pool of triantennary plasma N-glycans with α2,6-sialylation36, and changes in their levels and 
glycosylation might also be the major cause for the positive association of the respective glycan trait (A3E) with 
peritonitis. Notably, in our global approach we were not able to trace back the origin of the relevant glycan traits 
to their protein carriers. However, as for the diantennary, fucosylated, non-sialylated glycans in the serum and 
effluent of PD patients, we assume that these are largely IgG-derived as we deduce from previous studies available 
on human serum and plasma glycomes36.
Inflammation markers and peritoneal function parameters. All tested inflammatory markers were positively 
associated with the degree of triantennary α2,6-sialylation of effluent proteins (EfA3E, Table 3). At the same 
time, the relative abundance of triantennary glycans (A3) and the degree of fucosylation of triantennary glycans 
(A3F) in serum and/or effluent was positively correlated with the IL-6 and IL-8 concentration in the effluent. 
Core and antenna fucosylation of acute-phase proteins has been shown to be increased in various disease condi-
tions, such as chronic pancreatitis47, rheumatoid arthritis48 and inflammation related to cancer49. Furthermore, 
literature demonstrates that α2,6-sialyltransferase expression can be induced by different pro-inflammatory 
cytokines in human endothelial cells50. This enzyme was furthermore secreted into the medium50, indicating that 
α2,6-sialylation of circulating glycoproteins may occur in vivo upon inflammation.
Previously, various proteins were found to be differentially expressed in PD patients with low and high values 
of peritoneal transport, including glycoproteins such as haptoglobin, alpha-1 antitrypsin, and immunoglobu-
lins26,51. Moreover, protein losses in PDE were found to be higher in high-transport patients as defined by higher 
D/P creatinine after 4 hours (PET) values51. Therefore, we analysed a possible association of serum and effluent 
protein glycosylation with transport characteristics in PD. Ultrafiltration was not associated with glycan traits 
after adjustment for confounders (Supporting Information Table S-3B), while D/P creatinine after 4 hours (PET) 
was positively associated with triantennary glycans and the α2,6-sialylation of those, and inversely associated 
with diantennary glycans and α2,3-sialylation of those in the effluent, but not serum (Table 3). The same glycan 
traits were associated with TGFβ-1 and VEGF concentrations (Table 3), which have been linked to pathological 
changes of the peritoneum upon PD18. Importantly, TGFβ-1-induced EMT in the context of tumour progression 
was found to be promoted by an increased expression of α2,6-sialyltranferase 152. A similar mechanism might 
have led to the predominance of α2,6-sialylation of effluent N-glycans regarding its associations with detrimental 
PD markers/parameters in our data.
Furthermore, galactosylation of diantennary glycans was inversely correlated with effluent TGFβ-1 concen-
trations, but positively correlated with CA-125 that is considered as a marker of mesothelial cell mass, which is 
decreasing in PD patients developing complications, such as encapsulating peritoneal sclerosis53. Galactosylation 
of serum diantennary N-glycans was shown to be decreased in liver cirrhosis29, a pathological condition preceded 
by fibrotic tissue transformation that might show similarities to the pathological changes upon long-time PD. 
Both, a higher α2,6-sialylation of diantennary glycans (A2E) and a higher galactosylation of diantennary glycans 
in effluent with, at the same time, lower abundance of IgG-glycans seems to reflect a better clinical state, as indi-
cated by their positive associations with CA-125 and inverse associations with peritonitis (Table 3).
Summary. As demonstrated by using a recently developed MALDI-TOF-MS method with linkage-specific sialic 
acid derivatisation, α2,6-sialylation of triantennary N-glycans in PD effluent seems to reflect adverse events upon 
long-term PD. Furthermore, a relative increase in IgG-related glycans and a lower galactosylation of diantennary 
glycans appeared to be related to peritonitis and the loss of mesothelial cell mass. Thus, glycosylation of effluent 
proteins in PD patients might bear some potential as future biomarkers of peritoneal functionality, hopefully 
aiding the detection of early-stage functionality changes – already before cytokine secretion and a destructive 
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Glycan trait Peritonitis DPCrea4 IL-6 IL-8 MCP-1 HA TGFβ-1 VEGF CA-125
Sample_Trait Description OR (95% CI) Regression coefficient B (95% CI)
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Table 3. Overview of the main associations of clinical parameters with N-glycans. Displayed are odds ratios 
(OR) derived from logistic regression and regression coefficients B from linear regression along with their 95% 
confidence intervals, both using GEE for a robust estimation of the standard errors. Only associations with 
p < 0.05 and a 10%-cutoff for the change in estimate by confounders are shown, while associations not matching 
these criteria are listed in Supporting Information Table S-3 (here marked with a)). Thus, high-mannose trait 
(M) in either serum or effluent, in addition to A2F, A2L, A3L, A2E and IgG in serum are not listed. Associations 
for direct traits with the compositions H3N4F1 and H3N5F1 were only tested for effluent, but not serum. Se, 
glycans from serum; Ef, glycans from PD effluent; H, hexose; N, N-acetylhexosamine; F, fucose. The following 
models were used: 0, crude analysis; 1, model 1 with adjustment for age, sex, diabetes; 2, model 2 with adjustment 
for CAPD/APD, time on PD and Dianeal/Physioneal group; 3, model 1 + 2. Relative signal intensities of the 
derived glycan traits were calculated as %-values, and levels of IL-6, IL-8, MCP-1, HA, TGFβ-1, VEGF and CA-
125 were ln-transformed prior to regression analysis. Negative and positive associations are formatted in italic 
and bold, respectively; not tested associations are depicted as [---]. For calculations of derived trait abundances, 
see Supporting Information Table S-1 and S-2.
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inflammatory cascade would take place. However, future research should include studies of the respective protein 
carriers, such as IgG, acute-phase proteins originating from the liver, or specific glycoproteins locally produced 
in the peritoneum, e.g. CA-125.
Methods
Study population and data collection. The current study is embedded in an open label multi-centre 
prospective randomised clinical trial, which enrolled 94 PD patients (aged over 18 years) from twelve different 
hospitals in the Netherlands during a period of 24 months (EudraCT 2006-001570-25). The study was approved 
by the medical ethics committee of the VU University Medical Center (‘medisch ethische toetsingscommissie van 
VUmc’), and was confirmed at all participating centres (see ref.31 for more details). The methods were carried out 
in accordance with the relevant guidelines and regulations (METC protocol number 2005.183). All study partic-
ipants gave written informed consent.
Patients included in the randomised part of the study were treated with standard lactate-buffered PD fluid 
(Dianeal®, Baxter Healthcare, USA), and either continued on Dianeal (group 1, n = 38), or switched to a bicarbo-
nate/lactate-buffered PD fluid (Physioneal®, Baxter Healthcare, USA; group 2, n = 40). A third group of patients 
(group 3, n = 16) was not included in the randomised part of the study and was already treated with Physioneal 
before the study period. They had never used Dianeal before. Prior to study start all patients had to undergo PD 
treatment for at least 6 weeks. Episodes of peritonitis or exit site infections that occurred within 6 weeks before 
entering the study, or use of non-glucose based dialysis solutions, except icodextrin, were considered exclusion 
criteria. Block randomisation per centre was performed centrally at the VU University Medical Center (4 patients 
per block and 2 patients assigned to each treatment per block).
Sample preparation and measurement. Serum and 24-hours (overnight) dialysate samples were col-
lected at 0, 6, 12, 18 and 24 months and stored at -80 °C until laboratory analysis.
Peritoneal Equilibrium Test (PET). A 4-hour PET using 3.86% Dianeal or Physioneal was performed at 0, 12 
and 24 weeks in order to assess peritoneal membrane function54. If a patient did not tolerate the 3.86% solution 
because of hypotension, 2.27% was used. Serum and effluent creatinine levels were determined using a cobas® 
8000 immunoanalyser (Roche Diagnostics, Rotkreuz, Switzerland).
Peritonitis events. Peritonitis events were recorded and defined as a dialysate having a cell count higher than 
100/μL, of which more than 50% were polymorphonuclear leukocytes. Effluents were cultured to define the 
microorganisms involved, and for the diagnosis also symptoms such as abdominal pain, fever and/or cloudy 
dialysate were taken into account55. Peritonitis relapses (peritonitis with the same organism or sterile episode 
occurring within 4 weeks of an earlier episode) were counted as 1 episode.
Analysis of effluent cytokines and serum lipids. Assays for cytokine detection were performed in cell-free super-
natants of effluents collected at 0, 6, 12, 18 and 24 months. A multiparameter Bio-Plex 200 chemiluminometric 
bead assay kit (Biorad, Hercules, California, Texas, USA) was used to measure VEGF, IL-6, IL-8, and MCP-1 lev-
els. HA was determined in an ELISA-based assay according to Fosang et al.56 using immobilised HA and compe-
tition for the binding of biotinylated HA-binding protein by HA-containing samples. TGFβ-1 was measured using 
a quantitative ELISA (Promega Corporation, Madison, USA, detection limit 32 pg/mL). A two-side sandwich 
immunoassay using direct chemiluminometric technology (Centaur OV-assay Bayer Diagnostics, Tarrytown, 
NY, USA) was used to determine CA-125 levels.
HsCRP was measured using a sensitive, enzyme-linked assay able to detect values below the detection limit 
of standard assays (DakoCytomation, Glostrup, Denmark). HbA1c was measured using the HA-8160 (Adams 
A1c) analyser which uses an HPLC cation exchange method (Menarini Diagnostics Benelux, Valkenswaard, The 
Netherlands). Serum lipids were measured by a cobas® 8000 immunoanalyser (Roche Diagnostics, Rotkreuz, 
Switzerland).
Sample treatment and glycomic analysis. PVDF membrane N-glycan release: N-glycans were released from the 
protein fraction on a protein-binding hydrophobic Immobilon-P Membrane (PVDF) plate (Merck Millipore, 
Darmstadt, Germany)57. Throughout the glycomic sample preparation and analysis, ultrapure water (MQ) was 
used (≥18.2 MΩ at 25 °C, Merck Millipore). The membrane was preconditioned by washing 2× with 200 µL 70% 
ethanol followed by two washes with 200 µL 100 mM NaHCO3. Biological samples were applied by mixing 72.5 µL 
8 M GuHCl with 2.5 µL 200 mM dithiothreitol with 25 µL sample (2.5 times diluted serum and undiluted PDE) 
on the membrane and washing 4× with 200 µL buffer. Subsequently, 1 mU recombinant peptide-N-glycosidase 
F (PNGase F; Roche Diagnostics, Mannheim, Germany) was applied to the sample in 50 µL 100 mM NaHCO3 
buffer, followed by overnight-incubation at 37 °C in a humidity chamber. The released N-glycans were recovered 
by centrifugation at 2000 rpm.
Derivatisation for MALDI-TOF-MS: The released glycans were derivatised for a selective ethyl-esterification of 
α2,6-linked N-acetylneuraminic acids and lactonisation of α2,3-linked N-acetylneuraminic acids32. The derivati-
sation mixture was prepared by mixing 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (Fluorochem, Hadfield, 
UK) with 1-hydroxybenzotriazole (Sigma-Aldrich, Steinheim, Germany), to a final concentration of 0.25 M in 
ethanol (Merck, Darmstadt, Germany). The reaction was performed in 20 μL of the derivatisation mixture with 
1 µL released glycans from serum and 2 µL released glycans from PDE. The plate was sealed to prevent evapora-
tion and incubated 1 h at 37 °C. To allow protein precipitation 20 µL of acetonitrile (Biosolve, Valkenswaard, the 
Netherlands) was added, further incubated for 15 min at −20 °C before proceeding with glycan enrichment and 
analysis by matrix-assisted laser desorption/ionisation time-of-flight mass spectrometry (MALDI-TOF-MS).
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Hydrophilic-interaction liquid-chromatographic purification for MALDI-TOF-MS: Glycan enrichment was per-
formed by cotton hydrophilic-interaction liquid-chromatography as previously described58. The samples were 
allowed to return to room temperature before proceeding. The tips with cotton as stationary phase (3 mm cotton 
thread, ca. 190 µg; Pipoos, Utrecht, the Netherlands) were washed and equilibrated with 3 × 20 μL of MQ and 
3 × 20 μL of 85% acetonitrile; sample loading was achieved by pipetting 20× into the reaction mixture, the wash-
ing step consisted of pipetting 3 × 20 μL 85% acetonitrile 1% trifluoroacetic acid (Merck), 3 × 20 μL 85% acetoni-
trile. Samples were finally eluted in 10 μL MQ.
MALDI-TOF-MS measurement: For MALDI-TOF-MS analysis, 1 μL of purified serum- and 2 µL of purified 
PDE glycan solution was spotted on a MTP AnchorChip 800/384 TF MALDI target (Bruker Daltonics, Bremen, 
Germany), and 1 μL of matrix (5 mg/mL 2,5-dihydroxybenzoic acid (Bruker Daltonics), 1 mM NaOH in 50% ace-
tonitrile), mixed on plate and left to dry. To achieve uniform crystals, the spot was tapped with 0.2 μL ethanol, caus-
ing rapid recrystallisation. All analyses were performed on an ultrafleXtreme MALDI-TOF/TOF-MS equipped 
with a Smartbeam II laser, controlled by proprietary software flexControl 3.4 Build 119 (Bruker Daltonics). The 
MALDI-TOF instrument was operated in reflectron positive ion mode, calibrated on the known masses of a pep-
tide calibration standard (Bruker Daltonics). For sample measurements 20,000 laser shots were accumulated at a 
laser frequency of 2,000 Hz, using a complete-sample random walk with 200 shots per raster spot.
Data processing. The mass spectra were extracted and processed for quality control and relative quantita-
tion of analytes. The raw spectra were exported from flexAnalysis 3.4 (Build 76; Bruker Daltonics) as text files 
(x,y), and further processed by MassyTools (version 0.1.8.0)59. First, internal calibration was performed based on 
a predefined list of 5 analytes (peaks 2, 3, 5, 9, 18 in Supporting Information Table S-1). Mass spectra presenting a 
signal-to-noise ratio (S/N) of 9 or above for the calibration analytes were included for further analysis (S/N based 
on the MinMax algorithm). Furthermore, 10 spectra were excluded because their “fraction of analyte area above 
S/N 9” was below 3 standard deviations (SD) of the mean.
Structural assignment was based on the putative compositional features (hexose = H, N-acetylhexosamine = N, 
fucose = F, N-acetylneuraminic acid = E or L for α2,6- and α2,3-linked variants, respectively). After the exclusion 
of compositions with interfering peaks (n = 15), background-subtracted peak areas were normalised to the sum 
of the areas of all the 26 peaks from the final list of 26 glycan compositions. Derived traits were calculated based 
on the compositional features based on established knowledge of the human plasma N-glycome and its biosyn-
thetic pathways (Supporting Information Table S-1 and S-2)32–34. For example, bisection of diantennary glycans 
was assumed rather than an agalactosylated third antenna for H5N5E1F1. Finally, relative intensities were multi-
plied by the factor of 100 prior to statistical analysis.
Statistical analysis. Effluent marker levels, used as dependent variables, were ln-transformed prior to sta-
tistical analysis due to their non-normal distribution. When generating association heatmaps, derived glycan trait 
values were scaled (mean subtraction and division by SD) to obtain interpretable estimates, i.e. t-statistics and 
Wald statistics in case of linear and logistic regression, respectively.
The generation of heatmaps for baseline data was carried out by using the ‘rquery.cormat’ function and 
‘ggplot2’ and ‘WGCNA’ libraries60. To this end, R version 3.2.2 in an RStudio environment was employed (RStudio 
Team, Boston, MA).
Paired Wilcoxon signed-rank tests (two-tailed) were performed in IBM SPSS Statistics 23 to compare serum 
vs. effluent glycosylation levels at baseline as well as to compare baseline vs. 24-months levels of glycan traits that 
showed changing trends towards the end of the study.
Analysis of the longitudinal data was further performed by using the Generalized Estimated Equations (GEE) 
method with an exchangeable working correlation matrix in IBM SPSS Statistics 23. By using ‘individual’ as the 
grouping variable, multiple measurements within an individual were taken into account, providing more robust 
data. A binary logistic GEE model was used for the evaluation of the association of glycan traits with peritonitis 
occurrence, while a linear model was applied to estimate the association of glycan traits with effluent markers and 
peritoneal transport parameters, i.e. the (log-transformed) concentration of TGFβ-1, IL-6, IL-8, MCP-1, VEGF, 
CA-125 and HA, as well as ultrafiltration during PET and D/P creatinine after 4 hours (PET). Next to performing 
crude GEE-analysis, we adjusted for confounders in three models: model 1: age, sex and diabetes; model 2: treat-
ment modality (CAPD or APD), time on PD and treatment group; model 3: a combination of all confounders of 
model 1 and model 2. Age and time on PD were added as continuous variables, whereas sex, diabetes, treatment 
modality, and treatment group were added as categorical variables. Regression coefficients and odds ratios are 
given with 95% confidence intervals.
Data availability. The extracted glycomics data including all time points available per patient is compiled in 
Supporting Information Table S-4. The MS glycomics raw data generated and analysed during the current study 
as well as the clinical data from individuals are available from the corresponding author on reasonable request.
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